Posted by Michael Wonder on 11 Jul 2022
T2 Biosystems receives FDA breakthrough device designation for the T2Lyme panel
11 July 2022 - Molecular diagnostic test for early detection of Lyme disease.
T2 Biosystems announced today the U.S. FDA has granted breakthrough device designation for the company’s T2Lyme Panel.
